Search for information about a product,
therapeutic area or event

Search

Media, investors, advocacy organizations and others, please contact us here.

Medical Information IgAN

FILSPARI (sparsentan) – 2-Year Results from the Phase 3 PROTECT Study Published in The Lancet

Learn more
Posters IgAN

Sparsentan as First-Line Treatment of Incident Patients With IgA Nephropathy:​ Preliminary Findings From the SPARTAN Trial

Learn More
Abstracts IgAN

Clinical Predictors of Major Adverse Kidney Disease Events in Patients with IgA Nephropathy

View
Abstracts IgAN

Sparsentan receptor occupancy modeling, clinical actions, and safety

View
Abstracts IgAN

Sparsentan as First-Line Treatment of Incident Patients with IgA Nephropathy: Preliminary Findings from the SPARTAN Trial

View
Abstracts IgAN

Sparsetan Reduces Proteinuria in Patients with Immunoglobulin A Nephropathy (IgAN): Interim Results of the PROTECT Study

View
Abstracts IgAN

Proteinuria and disease progression in the RaDaR IgAN cohort

View
Abstracts IgAN

Dual blockade of endothelin A and angiotensin II type 1 receptors with sparsentan is protective in thegddY mouse model of IgA nephropathy to a greater extent than losartan

View
Posters IgAN

Estimating delay in time to kidney failure ordeath for treatment effects on proteinuria inIgA nephropathy

Learn More
Posters IgAN

Matching-adjusted indirect comparison of sparsentan vs. delayed-release formulationbudesonide for proteinuria reduction in adults with IgA nephropathy

Learn More
Posters FSGS

Understanding the Impact of Immunoglobulin ANephropathy (IgAN) and Focal Segmental Glomerulosclerosis (FSGS) on Patients and Care-Partners Study(HONUS): Updated Results for IgAN in the United States (US)

Learn More
Abstracts IgAN

Clinical Predictors of Major Adverse Kidney Disease Events in Patients with IgA Nephropathy

View
Abstracts IgAN

Preliminary Findings From the Phase 2 EPPIK Study of Sparsentan in Pediatric Patients With Selected Proteinuric Glomerular Diseases

View